Tech Company Financing Transactions

Avrobio Funding Round

On 2/2/2018, Avrobio raised $60 million in Series B investment from Cormorant Asset Management, Surveyor Capital and Aisling Capital.

Transaction Overview

Company Name
Avrobio
Announced On
2/2/2018
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors

Cormorant Asset Management (Lead Investor)

Surveyor Capital (Lead Investor)

Aisling Capital

Atlas Venture (Bruce Booth)

Brace Pharma

Clarus (Scott Requadt)

Eventide Asset Management

Morningside Group

SV Health Investors (Joshua Resnick)

Proceeds Purpose
Proceeds from the financing will be used to advance multiple gene therapies from AVROBIO's proprietary lentiviral platform, including the company's lead gene therapy, AVR-RD-01, currently in Phase 1 for Fabry disease, as well as three additional gene therapies for other lysosomal storage disorders, Gaucher disease, cystinosis and Pompe disease.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 300 201
Cambridge, MA 02139
USA
Phone
617-914-8420
Website
www.avrobio.com
Email Address
[email protected]
Overview
AVROBIO is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating AVROBIO is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies.
Profile
Avrobio LinkedIn Company Profile
Social Media
Avrobio Company Twitter Account
Company News
Avrobio News
Facebook
Avrobio on Facebook
YouTube
Avrobio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Geoff MacKay
  Geoff MacKay LinkedIn Profile  Geoff MacKay Twitter Account  Geoff MacKay News  Geoff MacKay on Facebook
Chief Scientific Officer
Chris Mason
  Chris Mason LinkedIn Profile  Chris Mason Twitter Account  Chris Mason News  Chris Mason on Facebook
Vice President
Kathryn McNaughton
  Kathryn McNaughton LinkedIn Profile  Kathryn McNaughton Twitter Account  Kathryn McNaughton News  Kathryn McNaughton on Facebook
VP - Bus. Development
Deanna Petersen
  Deanna Petersen LinkedIn Profile  Deanna Petersen Twitter Account  Deanna Petersen News  Deanna Petersen on Facebook
VP - Operations
Kim Warren
  Kim Warren LinkedIn Profile  Kim Warren Twitter Account  Kim Warren News  Kim Warren on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/2/2018: SaaSOptics venture capital transaction
Next: 2/2/2018: Lambda School venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.